<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297670</url>
  </required_header>
  <id_info>
    <org_study_id>HPV2020-5037</org_study_id>
    <nct_id>NCT04297670</nct_id>
  </id_info>
  <brief_title>HPV Prevalence in 16-20 Year Old Males</brief_title>
  <official_title>Evaluation of the Impact of Quebec HPV Immunization Program: Prevalence of HPV Types in 16-20 Year Old Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Quebec, 18 birth cohorts of girls were vaccinated against HPV (aged 9 to 29 years in
      2020). With an observed vaccination coverage of &gt;80% an important herd effect might be
      expected. This study aim is to measure the HPV types prevalence in unvaccinated sexually
      active boys aged 16 to 20 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An HPV immunization program is in place in Quebec since 2008. By 2020 18 birth cohorts of
      girls were eligible for vaccination. Vaccine uptake with at least one dose of vaccine was
      &gt;80%. With such a high vaccine uptake an important herd immunity might be expected. The main
      objective of this study is to measure the prevalence of different HPV types in unvaccinated
      sexually active boys aged 16 to 20 years. This is a cross sectional study which includes one
      visit for all participants. Self sampling technic is used. During this phase of the study a
      total of 681 boys will be recruited. An additional phase of the study will be conducted at
      the condition that the prevalence of HPV6/11/16/18/31/33/45/52 and 58 in unvaccinated boys
      will be at least 8.65%. The second phase of the study if conducted will measure the
      prevalence of the same HPV types in 681 vaccinated boys of the same age.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of HPV 6/11/16/18/31/33/45/52 and 58</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Unvaccinated sexually active 16-20 year old boys will be tested</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of 31 HPV types</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Unvaccinated sexually active 16-20 year old boys will be tested</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">681</enrollment>
  <condition>HPV Infection</condition>
  <arm_group>
    <arm_group_label>Unvaccinated against HPV boys</arm_group_label>
    <description>Sexually active unvaccinated against HPV 16-20 years old boys.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measurement of HPV types prevalence</intervention_name>
    <description>Self collected genital samples to be tested for the presence of different HPV types.</description>
    <arm_group_label>Unvaccinated against HPV boys</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Self collected genital sample.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Sexually active 16-20 years old boys studying at a professional school or college.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  unvaccinated against HPV

          -  sexually active

        Exclusion Criteria:

          -  received an HPV vaccine

          -  non sexually active
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>gender identity</gender_description>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chantal Sauvageau, MD, MSc</last_name>
    <phone>1 418 650 5115</phone>
    <phone_ext>6368</phone_ext>
    <email>chantal.sauvageau@inspq.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vladimir Gilca, MD, PhD</last_name>
    <phone>1 418 650 5115</phone>
    <phone_ext>6510</phone_ext>
    <email>vladimir.gilca@inspq.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laval University Research Hospital Center</name>
      <address>
        <city>Quebec</city>
        <zip>G1E7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chanta Sauvageau, MD, MSc</last_name>
      <phone>418 650 5115</phone>
      <phone_ext>6368</phone_ext>
      <email>chantal.sauvageau@inspq.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Vladimir Gilca, MD, PhD</last_name>
      <phone>4186667000</phone>
      <phone_ext>368</phone_ext>
      <email>vladimir.gilca@inspq.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Chantal Sauvageau, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevalence</keyword>
  <keyword>Boys</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared with any researcher outside this study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

